Genzyme Corporation has reported that the global supply of Thyrogen® will fluctuate through July, 2011 causing temporary shortages in certain countries. Genzyme anticipates a shortage in the United States beginning in mid-April and extending through mid-June. Healthcare providers and patients should plan accordingly. The selective use of Thyrogen®, or the delay of its use, until the shortage ends may help limit the shortage for those most likely to benefit from its immediate use. Thyrogen® use should not be scheduled until its availability is confirmed through your normal method of obtaining it.
Genzyme reports that all Thyrogen® released from both Genzyme’s Allston plant and from Hospira has met all applicable quality standards and is safe for use in patients for whom it is indicated.
Additional information may be found at http://www.thyrogen.com/home/thy_home.asp
AMERICAN THYROID ASSOCIATION® , ATA® , THYROID® , CLINICAL THYROIDOLOGY® , and the distinctive circular logo are registered in the U.S. Patent and Trademark Office as trademarks of the American Thyroid Association® , Inc.